Novo Holdings establishes new firm managed by biotech veterans

Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.

Photo: Novo Holdings / PR

Novo Holdings, the holdings company which owns Novo Nordisk, has founded a Danish private limited company named Aloop Therapeutics, with Orphazyme co-founder Thomas Kirkegaard Jensen as a director and Sandion Oncology CEO Bo Rode Hansen as chair of the board, according to a filing on the Danish Central Business Register (CVR).

Novo Holdings doesn’t want to comment on the new firm, the purpose of which has only been described as ”research, development and commercialization of drugs,” according to the document.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs